- Remove All
- Your shopping cart is currently empty
CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated is expressed in HEK293 mammalian cells with N-His and C-Avi tag. The predicted molecular weight is 26.4 kDa and the accession number is Q5QGZ9-2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $814 | 7-10 days | |
500 μg | $3,250 | 7-10 days | |
1 mg | $5,440 | 7-10 days |
Biological Activity | Immobilized Anti-CLEC12A Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CLEC12A, His Tag with the EC50 of 0.41μg/ml determined by ELISA. |
Description | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated is expressed in HEK293 mammalian cells with N-His and C-Avi tag. The predicted molecular weight is 26.4 kDa and the accession number is Q5QGZ9-2. |
Species | Human |
Expression System | HEK293 Cells |
Tag | N-His, C-Avi |
Accession Number | Q5QGZ9-2 |
Synonyms | PRO34150,MICL,HECL,DLEC,DCAL-2,DCAL2,CLL-1,CLL1,CLECSF7,CLECSF11,CLEC12A,CD371,CD303 |
Construction | His65-Ala265 |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Molecular Weight | 26.4 kDa (predicted). Due to glycosylation, the protein migrates to 38-50 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. |
Research Background | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.